KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $1.4 billion.

  • Boston Scientific's Cash from Operations fell 631.87% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 3199.42%. This contributed to the annual value of $4.5 billion for FY2025, which is 3199.42% up from last year.
  • Boston Scientific's Cash from Operations amounted to $1.4 billion in Q4 2025, which was down 631.87% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's Cash from Operations ranged from a high of $1.5 billion in Q4 2024 and a low of -$58.0 million during Q1 2022
  • Its 5-year average for Cash from Operations is $693.4 million, with a median of $650.5 million in 2021.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 46883.12% in 2021, then tumbled by 12042.25% in 2022.
  • Quarter analysis of 5 years shows Boston Scientific's Cash from Operations stood at $478.0 million in 2021, then skyrocketed by 68.83% to $807.0 million in 2022, then grew by 18.59% to $957.0 million in 2023, then soared by 52.14% to $1.5 billion in 2024, then dropped by 6.32% to $1.4 billion in 2025.
  • Its Cash from Operations stands at $1.4 billion for Q4 2025, versus $1.3 billion for Q3 2025 and $1.3 billion for Q2 2025.